A Phase 4 interventional study of Rosuvastatin and Atorvastatin in Metabolic Syndrome X, sponsored by AstraZeneca. Completed at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-11.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Metabolic Syndrome with a site in Korea, Republic of — 4 open to participants now, 4 under way, none of them phase 3. Metabolic Syndrome · Korea, Republic of.
Among the 53 studies in Metabolic Syndrome with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2006, is one of 11 in phase 4, and was the 3rd registered.
2,118 studies on the registry are indexed under Metabolic Syndrome; 348 are open to participants now.
Browse Metabolic Syndrome studies →4 of the 53 studies in Metabolic Syndrome with a site in Korea, Republic of are open now. Recruiting first, the newest first:
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 40+
Hallym University · Sites in Korea, Republic of
Ages 20–70
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 60 across 1,573 interventional studies indexed under Metabolic Syndrome.
Median enrollment 67 across the 31 interventional studies, 150 across the 22 observational. Of the 31 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 53 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 9 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Metabolic Syndrome with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07523971JW PharmaceuticalEfficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Metabolic Syndrome with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.
Inclusion Criteria:
Presence of 3 or more of the following criteria;
Elevated LDL-C ;
Drug: Rosuvastatin
Drug: Atorvastatin
10mg
Also known as: Crestor
10mg
Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6
Samples for evaluation from all investigational sites will be delivered by courier to the central laboratory within 24 hours of blood being drawn. This outcome will be calculated by using the result of ApoB and ApoA1.
Time frame: Baseline and 6 weeks
Percentage of Subjects Reaching Their LDL-C Target Goal
Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C target goal. LDL-C target goals are \<70mg/dl, \<100mg/dl and \<130mg/dl according to their baseline conditions (presence of Coronary heart disease and risk factors and grade of Framingham 10-Year risk).
Time frame: Baseline and 6 weeks
Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal
Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C \& non HDL-C target goal.
Time frame: Baseline and 6 weeks
Percentage Change of Glucose Level
Using laboratory test, mean change of glucose level was investigated.
Time frame: Baseline and 6 weeks
Percentage Change of Insulin Resistance Using HOMA-R
HOMA-R was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: HOMA-R = insulin\* glucose/22.5
Time frame: Baseline and 6 weeks
Percentage Change of Insulin Resistance Using QUICKI
QUICKI was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: QUICKI = 1/\[log(insulin) + log(glucose)\].
Time frame: Baseline and 6 weeks
Percentage Reduction of Low-Density Lipoprotein-C (LDL-C)
Calculate the percentage reduction of LDL-C
Time frame: Baseline and 6 weeks
Percentage Change of Total Cholesterol (TC)
Calculate the percentage change of total cholesterol level
Time frame: Baseline and 6 weeks
Percentage Change of High-Density Lipoprotein-C (HDL-C)
Calculate the percentage change of HDL-C level
Time frame: Baseline and 6 weeks
Percentage Change of Triglycerides (TG)
Calculate the percentage change of Triglycerides.
Time frame: Baseline and 6 weeks
Percentage Change of Apolipoprotein A1 (ApoA1)
Calculate the percentage change of Apolipoprotein A1
Time frame: Baseline and 6 weeks
Percentage Change of Apolipoprotein B (ApoB)
Calculate the percentage change of apolipoprotein B
Time frame: Baseline and 6 weeks
A total of 613 subjects were enrolled in the study at 13 centres, of whom 258 were randomized to treatment with rosuvastatin (n=132) or atorvastatin (n=126). Subjects were recruited throughout South Korea from September 2006 to June 2008.
| Milestone | Rosuvastatin | Atorvastatin |
|---|---|---|
| Started | 132 | 126 |
| Completed | 126 | 121 |
| Not completed | 6 | 5 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 5 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
Samples for evaluation from all investigational sites will be delivered by courier to the central laboratory within 24 hours of blood being drawn. This outcome will be calculated by using the result of ApoB and ApoA1.
| percent change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6 | -44.40 ± 14.70 | -36.50 ± 14.10 |
Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C target goal. LDL-C target goals are \<70mg/dl, \<100mg/dl and \<130mg/dl according to their baseline conditions (presence of Coronary heart disease and risk factors and grade of Framingham 10-Year risk).
| percentage of participants | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage of Subjects Reaching Their LDL-C Target Goal | 88.20 | 75.40 |
Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C \& non HDL-C target goal.
| percentage of participants | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal | 78.80 | 66.70 |
Using laboratory test, mean change of glucose level was investigated.
| Percentage change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change of Glucose Level | -0.60 ± 10.10 | 2.78 ± 13.90 |
HOMA-R was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: HOMA-R = insulin\* glucose/22.5
| percentage change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change of Insulin Resistance Using HOMA-R | 28.00 ± 95.20 | 50.30 ± 287.50 |
QUICKI was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: QUICKI = 1/\[log(insulin) + log(glucose)\].
| percentage change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change of Insulin Resistance Using QUICKI | -1.27 ± 13.90 | -1.03 ± 15.00 |
Calculate the percentage reduction of LDL-C
| percentage reduction | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Reduction of Low-Density Lipoprotein-C (LDL-C) | -45.50 ± 15.10 | -37.90 ± 13.40 |
Calculate the percentage change of total cholesterol level
| percentage change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change of Total Cholesterol (TC) | -34.10 ± 11.20 | -28.80 ± 10.90 |
Calculate the percentage change of HDL-C level
| percentage change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change of High-Density Lipoprotein-C (HDL-C) | 9.90 ± 16.40 | 8.20 ± 18.70 |
Calculate the percentage change of Triglycerides.
| percentage change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change of Triglycerides (TG) | -17.20 ± 33.90 | -15.10 ± 43.50 |
Calculate the percentage change of Apolipoprotein A1
| percentage change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change of Apolipoprotein A1 (ApoA1) | 8.50 ± 12.40 | 4.20 ± 13.30 |
Calculate the percentage change of apolipoprotein B
| percentage change | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change of Apolipoprotein B (ApoB) | -40.50 ± 14.10 | -34.60 ± 13.00 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin | — | 0/129 (0%) | 0/129 (0%) |
| Atorvastatin | — | 4/124 (3.2%) | 0/124 (0%) |
| Event | Rosuvastatin | Atorvastatin |
|---|---|---|
| ArrhythmiaCardiac disorders | 0/129 | 1/124 |
| EnteritisGastrointestinal disorders | 0/129 | 1/124 |
| GastroenteritisGastrointestinal disorders | 0/129 | 1/124 |
| HaemorrhoidsGastrointestinal disorders | 0/129 | 1/124 |
| SyncopeNervous system disorders | 0/129 | 1/124 |
| Age Continuous(years) | Rosuvastatin | Atorvastatin | Total |
|---|---|---|---|
| 18 years | 57.5 ± 10.0 | 60.4 ± 9.0 | 58.9 ± 9.5 |
| Sex: Female, Male(Participants) | Rosuvastatin | Atorvastatin | Total |
|---|---|---|---|
| Female | 74 | 88 | 162 |
| Male | 58 | 38 | 96 |
The record gives a start of Sep 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin